10-1074-LS
- Generic Name
- 10-1074-LS
Lenacapavir and Broadly Neutralizing Antibodies Show Promise as Twice-Yearly HIV Treatment
• Phase II trial results demonstrate that lenacapavir combined with two broadly neutralizing antibodies (teropavimab and zinlirvimab) maintained viral suppression in 96% of participants over 26 weeks, comparable to daily oral regimens.
• The LTZ regimen (lenacapavir, teropavimab, zinlirvimab) could become the first complete twice-yearly HIV treatment option, potentially transforming care for people living with HIV by eliminating daily pill requirements.
• Pre-treatment screening for viral sensitivity to the antibodies is crucial, with approximately half of those screened showing high susceptibility to both antibodies, while others demonstrated sensitivity to at least one.
ViiV Healthcare Showcases Long-Acting HIV Innovations and Pipeline Advances at CROI 2025
• Real-world data presented at CROI 2025 demonstrates zero HIV acquisitions and high persistence with Apretude (cabotegravir LA) for PrEP across diverse populations, reinforcing its effectiveness in HIV prevention.
• Long-term follow-up data from multiple studies confirms the sustained efficacy and safety of Cabenuva (cabotegravir + rilpivirine LA) as a complete treatment regimen for people living with HIV.
• Late-breaking phase IIb data reveals promising results for an investigational broadly neutralizing antibody (VH3810109) in combination with cabotegravir LA, potentially expanding long-acting treatment options.
St. Jude's Narrative Medicine Program Reveals Impact of Long-Acting HIV Treatments Through Patient Stories
• St. Jude Children's Research Hospital's HIV clinical research program explores innovative long-acting treatments, including a groundbreaking six-month regimen combining antibodies and capsid inhibitors.
• A significant breakthrough led to FDA approval of injectable antiretrovirals (cabotegravir and rilpivirine) for youth aged 12 and older, offering an alternative to daily oral medications.
• Through narrative medicine approach, trial participants share personal experiences, highlighting the human impact of HIV treatment advances while maintaining anonymity due to stigma.
ACTG Launches ACACIA Trial in Africa to Evaluate HIV Cure Strategy
• The ACTG has initiated the ACACIA (A5417) study, a Phase 2 trial, to assess the safety and efficacy of broadly neutralizing antibodies (bNAbs) in HIV treatment.
• ACACIA will evaluate the combination of 3BNC117-LS and 10-1074-LS with antiretroviral therapy (ART) in adults living with HIV across four African countries.
• The trial includes an analytic treatment interruption (ATI) phase to determine if the intervention can control HIV in the absence of ART, a key step in HIV cure research.
• ACACIA aims to optimize the therapeutic benefit of bNAbs by administering them when viral load is high and assessing their long-lasting immunologic effects.
Gilead Presents New HIV Treatment Data, Including Long-Term Biktarvy Results and Novel Regimens
• Four-year data from the BICSTaR study confirms Biktarvy's sustained efficacy and safety in diverse HIV patients, showing high rates of virologic suppression and improved patient outcomes.
• ROSETTA registry analysis reveals distinct resistance pathways for integrase strand transfer inhibitors (INSTIs) based on prior exposure, informing future INSTI use in HIV treatment.
• Phase III ALLIANCE trial demonstrates Biktarvy's maintained efficacy in HIV/HBV co-infected adults over three years, with high rates of virologic suppression for both viruses.
• Investigational regimens like the once-daily bictegravir and lenacapavir combination and a novel weekly oral combination show promise for simplifying HIV treatment and addressing unmet needs.
Gilead Presents New HIV Treatment and Prevention Data at HIV Glasgow 2024
• Gilead's PURPOSE 2 trial results show lenacapavir's potential as a twice-yearly HIV prevention option for cisgender men and gender-diverse individuals.
• Four-year outcomes from the BICSTaR study confirm the consistent efficacy and safety of Biktarvy in diverse HIV patients with comorbidities.
• Phase 2 study data highlights a promising once-weekly oral combination of islatravir and lenacapavir for HIV treatment.
• Gilead's research at HIV Glasgow 2024 underscores its commitment to innovative HIV therapies and prevention strategies.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath